Acquisition by Zanganeh Mahkam of 20000 shares of Summit Therapeutics at 3.71 subject to Rule 16b-3

SMMT Stock  USD 19.00  0.58  3.15%   
Slightly above 69 percent of all Summit Therapeutics' private investors are curious in acquiring. The analysis of the overall investor sentiment regarding Summit Therapeutics PLC suggests that a large number of traders are confidant. Summit Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Summit Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Summit Therapeutics PLC Director, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Acquisition of 20000 common stock at 3.71 of Summit Therapeutics by Zanganeh Mahkam on 27th of March 2024. This event was filed by Summit Therapeutics PLC with SEC on 2024-03-27. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Summit Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Summit Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Summit Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Summit Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Summit Therapeutics PLC Historical Investor Sentiment

Investor biases related to Summit Therapeutics' public news can be used to forecast risks associated with an investment in Summit. The trend in average sentiment can be used to explain how an investor holding Summit can time the market purely based on public headlines and social activities around Summit Therapeutics PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Summit Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Summit Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Summit Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Summit Therapeutics.

Summit Therapeutics Fundamental Analysis

We analyze Summit Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Summit Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Summit Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Summit Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Summit Therapeutics PLC Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Summit Therapeutics stock to make a market-neutral strategy. Peer analysis of Summit Therapeutics could also be used in its relative valuation, which is a method of valuing Summit Therapeutics by comparing valuation metrics with similar companies.

Peers

Summit Therapeutics Related Equities

CDIOCardio Diagnostics   8.00   
0%
100.0%
KRONKronos Bio   3.45   
0%
43.0%
SONNSonnet Biotherapeutics   3.11   
0%
38.0%
CGEMCullinan Oncology   2.62   
0%
32.0%
OCEAOcean Biomedical   1.41   
0%
17.0%
NKTXNkarta   0.41   
0%
5.0%
ZVSAZyVersa Therapeutics   0.88   
11.0%
0%
ATNF180 Life   1.32   
16.0%
0%
KZRKezar Life   1.57   
19.0%
0%
ELEVElevation Oncology   1.64   
20.0%
0%
PHIOPhio Pharmaceuticals   2.37   
29.0%
0%
ZURAZura Bio   6.83   
85.0%
0%

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.